C26 Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 17.98 |
| 52 Week High | SEK 25.95 |
| 52 Week Low | SEK 14.74 |
| Beta | 1.23 |
| 11 Month Change | -26.16% |
| 3 Month Change | -19.01% |
| 1 Year Change | 19.39% |
| 33 Year Change | -48.15% |
| 5 Year Change | -37.79% |
| Change since IPO | -30.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| C26 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -12.7% | -0.4% | -0.4% |
| 1Y | 19.4% | -7.1% | 7.1% |
Return vs Industry: C26 exceeded the German Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: C26 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| C26 volatility | |
|---|---|
| C26 Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C26 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: C26's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 228 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.
CellaVision AB (publ) Fundamentals Summary
| C26 fundamental statistics | |
|---|---|
| Market cap | €441.27m |
| Earnings (TTM) | €12.96m |
| Revenue (TTM) | €63.58m |
34.1x
P/E Ratio6.9x
P/S RatioIs C26 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C26 income statement (TTM) | |
|---|---|
| Revenue | SEK 737.16m |
| Cost of Revenue | SEK 243.34m |
| Gross Profit | SEK 493.83m |
| Other Expenses | SEK 343.61m |
| Earnings | SEK 150.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 6.30 |
| Gross Margin | 66.99% |
| Net Profit Margin | 20.38% |
| Debt/Equity Ratio | 4.6% |
How did C26 perform over the long term?
See historical performance and comparison